Rui Pinto, PhD, Imperial College London, London, UK, describes the main findings from a metabolomics analysis of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). The FINGER trial was a randomized controlled trial investigating the effects on cognition of a 2-year multidomain lifestyle intervention vs regular health advice in 1260 at-risk older individuals. In this analysis, Dr Pinto wanted to investigate the metabolic effects of the intervention and their association with cognitive outcomes. Compared to controls, participants who undertook the FINGER intervention showed an increase in acylcarnitines and a decrease in sphingomyelins with an odd number of carbon atoms. Most notably, it was found that individuals who had anti-inflammatory metabolites at the start of the FINGER trial tended to have better cognition after the 2-year intervention than those who had pro-inflammatory metabolites at baseline. Future research will aim to understand which elements of the multidomain intervention affected which metabolites. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
